Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	Cell Press 2017

Những quyển sách tương tự

Myelodysplastic syndromes: moving towards personalized management
Bằng: Eva Hellström-Lindberg, et al.
Được phát hành: (2020-07-01)

Spliceosome mutations: 1 plus 1 does not always equal 2
Bằng: Pellagatti, A, et al.
Được phát hành: (2020)

Reduced translation of GATA1 in Diamond-Blackfan anemia.
Bằng: Boultwood, J, et al.
Được phát hành: (2014)

SF3B1 mutant myelodysplastic syndrome: Recent advances
Bằng: Pellagatti, A, et al.
Được phát hành: (2020)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Bằng: Pellagatti, A, et al.
Được phát hành: (2016)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Bằng: Jädersten, M, et al.
Được phát hành: (2009)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
Bằng: Follo, M, et al.
Được phát hành: (2019)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
Bằng: H. Dohner, et al.
Được phát hành: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
Bằng: Garcia-Manero, G, et al.
Được phát hành: (2021)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
Bằng: Boultwood, J, et al.
Được phát hành: (2012)

5q- syndrome.
Bằng: Boultwood, J, et al.
Được phát hành: (2012)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Bằng: Svensson, T, et al.
Được phát hành: (2014)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
Bằng: A. Schuh, et al.
Được phát hành: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
Bằng: Garcia-Manero, G, et al.
Được phát hành: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
Bằng: Garcia-Manero, G, et al.
Được phát hành: (2021)

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
Bằng: L. Adès, et al.
Được phát hành: (2020-11-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
Bằng: S. de Botton, et al.
Được phát hành: (2022-06-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
Bằng: Nikpour, M, et al.
Được phát hành: (2007)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
Bằng: Pellagatti, A, et al.
Được phát hành: (2009)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Bằng: R Edlin, et al.
Được phát hành: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Bằng: R Edlin, et al.
Được phát hành: (2010-05-01)

P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML
Bằng: A. Schnegg-Kaufmann, et al.
Được phát hành: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
Bằng: Garcia-Manero, G, et al.
Được phát hành: (2021)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
Bằng: Pellagatti, A, et al.
Được phát hành: (2009)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
Bằng: Pellagatti, A, et al.
Được phát hành: (2011)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Bằng: Pellagatti, A, et al.
Được phát hành: (2010)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
Bằng: Pellagatti, A, et al.
Được phát hành: (2008)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
Bằng: Pellagatti, A, et al.
Được phát hành: (2011)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
Bằng: Scharenberg, C, et al.
Được phát hành: (2011)

Gene expression profiling in the myelodysplastic syndromes.
Bằng: Pellagatti, A, et al.
Được phát hành: (2005)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
Bằng: Sara Mongiorgi, et al.
Được phát hành: (2023-02-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
Bằng: Armstrong, R, et al.
Được phát hành: (2017)

Advances in the 5q- syndrome.
Bằng: Boultwood, J, et al.
Được phát hành: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
Bằng: Pellagatti, A, et al.
Được phát hành: (2010)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
Bằng: Anjali Bhatt, et al.
Được phát hành: (2022-11-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
Bằng: Chiara R. Dart, et al.
Được phát hành: (2021-07-01)

NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING
Bằng: Nikpour, M, et al.
Được phát hành: (2009)

YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
Bằng: Nikpour, M, et al.
Được phát hành: (2009)

Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
Bằng: Nikpour, M, et al.
Được phát hành: (2009)

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
Bằng: Nikpour, M, et al.
Được phát hành: (2010)